Abstract
Rationale
Although competitive antagonism experiments are critical tools in the classification of potential pharmacotherapies, no studies have quantitatively compared the potencies of 5-HT2C receptor antagonists using the Schild regression analysis in vivo.
Objectives
To evaluate the behavioral effects of 5-HT2C receptor agonists and antagonists, a series of nonselective 5-HT2C receptor antagonists, the 5-HT2A/2C receptor antagonist ketanserin, the 5-HT2B receptor antagonist SB 204,741, the 5-HT2B/2C receptor antagonist SB 200,646, and the peripherally acting 5-HT2C receptor antagonist RS102221 were evaluated for their capacity to competitively antagonize the agonists MK212, mCPP, or BW723C86 in rats.
Materials and methods
Male Sprague–Dawley rats (N = 28) were trained to respond under a fixed ratio 10 schedule of food reinforcement. A multiple-trial, cumulative-dosing procedure was used to evaluate the capacity of the compounds to suppress response rates.
Results
MK212, mCPP, and the 5-HT2B receptor agonist BW723C86 dose-dependently decreased response rates. Only metergoline, mianserin, and methysergide produced a dose-dependent antagonism of the rate-decreasing effects of both mCPP and MK212. Apparent pA2 analysis indicated that metergoline, mianserin, and methysergide were approximately equipotent as antagonists overall. Metergoline and mianserin failed to block the rate-decreasing effects of BW723C86. Ketanserin, SB 200,646, SB 204,741, and RS102221 failed to block either mCPP or MK212, suggesting that 5-HT2A, 5-HT2B, or peripheral 5-HT2C receptors do not play a primary role in the rate-decreasing effects of these two agonists.
Conclusions
Taken together, these antagonism profiles suggest that the agonists MK212 and mCPP produce their rate-decreasing effects through a combination of 5-HT receptors with the 5-HT2C receptor playing a prominent but not exclusive role.
Similar content being viewed by others
References
Arunlakshana O, Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 14:48–58
Baxter GS (1996) Novel discriminatory ligands for 5-HT2B receptors. Behav Brain Res 73:149–152
Bonhaus DW, Bach C, DeSouza A, Salazar FH, Matsuoka BD, Zuppan P, Chan HW, Eglen RM (1995) The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br J Pharmacol 115:622–628
Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, McNeeley PM, Szczepanski K, Fontana DJ, Trinh J, Rocha CL, Dawson MW, Flippin LA, Eglen RM (1997) RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology 36:621–629
Brady LS, Barrett JE (1985) Effects of serotonin receptor antagonists on punished responding maintained by stimulus-shock termination or food presentation in squirrel monkeys. J Pharmacol Exp Ther 234:106–112
Burris KD, Sanders-Bush E (1992) Unsurmountable antagonism of brain 5-hydroxytryptamine2 receptors by (+)-lysergic acid diethylamide and bromo-lysergic acid diethylamide. Mol Pharmacol 42:826–830
Callahan PM, Cunningham KA (1995) Modulation of the discriminative stimulus properties of cocaine by 5-HT1B and 5-HT2C receptors. J Pharmacol Exp Ther 274:1414–1424
Conn PJ, Sanders-Bush E (1987) Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. J Pharmacol Exp Ther 242:552–557
Cunningham KA, Callahan PM, Appel JB (1986) Discriminative stimulus properties of the serotonin agonist MK212. Psychopharmacology (Berl) 90:193–197
Cussac D, Newman-Tancredi A, Quentric Y, Carpentier N, Poissonnet G, Parmentier JG, Goldstein S, Millan MJ (2002) Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols. Naunyn Schmiedebergs Arch Pharmacol 365:242–252
De Vry J, Schreiber R, Daschke A, Jentzsch KR (2003) Effects of serotonin 5-HT(1/2) receptor agonists in a limited-access operant food intake paradigm in the rat. Eur Neuropsychopharmacol 13:337–345
Dekeyne A, Girardon S, Millan MJ (1999) Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO 60-0175: a pharmacological analysis. Neuropharmacology 38:415–423
Fiorella D, Rabin RA, Winter JC (1995a) The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I. Antagonist correlation analysis. Psychopharmacology (Berl) 121:347–356
Fiorella D, Rabin RA, Winter JC (1995b) The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology (Berl) 119:222–230
Forbes IT, Kennett GA, Gadre A, Ham P, Hayward CJ, Martin RT, Thompson M, Wood MD, Baxter GS, Glen A et al (1993) N-(1-methyl-5-indolyl)-N’-(3-pyridyl)urea hydrochloride: the first selective 5-HT1C receptor antagonist. J Med Chem 36:1104–1107
Gleeson S, Ahlers ST, Mansbach RS, Foust JM, Barrett JE (1989) Behavioral studies with anxiolytic drugs. VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes. J Pharmacol Exp Ther 250:809–817
Gommans J, Hijzen TH, Maes RA, Olivier B (1998) Discriminative stimulus effects of mCPP: Evidence for a 5-HT2C receptor mode of action. Psychopharmacology (Berl) 137:292–302
Hamik A, Peroutka SJ (1989) 1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry 25:569–575
Hoyer D (1988a) Functional correlates of serotonin 5-HT1 recognition sites. J Recept Res 8:59–81
Hoyer D (1988b) Molecular pharmacology and biology of 5-HT1C receptors. Trends Pharmacol Sci 9:89–94
Kennett GA, Curzon G (1988) Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors. Br J Pharmacol 94:137–147
Kennett GA, Pittaway K, Blackburn TP (1994a) Evidence that 5-HT2c receptor antagonists are anxiolytic in the rat Geller–Seifter model of anxiety. Psychopharmacology (Berl) 114:90–96
Kennett GA, Wood MD, Glen A, Grewal S, Forbes I, Gadre A, Blackburn TP (1994b) In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist. Br J Pharmacol 111:797–802
Kennett GA, Wood MD, Bright F, Cilia J, Piper DC, Gager T, Thomas D, Baxter GS, Forbes IT, Ham P, Blackburn TP (1996) In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol 117:427–434
Labrecque J, Fargin A, Bouvier M, Chidiac P, Dennis M (1995) Serotonergic antagonists differentially inhibit spontaneous activity and decrease ligand binding capacity of the rat 5-hydroxytryptamine type 2C receptor in Sf9 cells. Mol Pharmacol 48:150–159
Mansbach RS, Barrett JE (1986) Effects of MK-212 (6-chloro-2[1-piperazinyl]pyrazine) on schedule-controlled behavior and their reversal by 5-HT antagonists in the pigeon. Neuropharmacology 25:13–19
McCreary AC, Filip M, Cunningham KA (2003) Discriminative stimulus properties of (+)-fenfluramine: the role of 5-HT2 receptor subtypes. Behav Neurosci 117:212–221
McMillan DE, Katz JL (2002) Continuing implications of the early evidence against the drive-reduction hypothesis of the behavioral effects of drugs. Psychopharmacology (Berl) 163:251–264
Meert TF, Melis W, Aerts N, Clincke G (1997) Antagonism of meta-chlorophenylpiperazine-induced inhibition of exploratory activity in an emergence procedure, the open field test, in rats. Behav Pharmacol 8:353–363
Millan MJ (2005) Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapies 60:441–460
Millan MJ, Peglion JL, Lavielle G, Perrin-Monneyron S (1997) 5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists. Eur J Pharmacol 325:9–12
Minnema DJ, Hendry JS, Rosecrans JA (1984) Discriminative stimulus properties of pizotifen maleate (BC105): a putative serotonin antagonist. Psychopharmacology (Berl) 83:200–204
Peroutka SJ (1986) Pharmacological differentiation and characterization of 5-HT1A, 5-HT1B, and 5-HT1C binding sites in rat frontal cortex. J Neurochem 47:529–540
Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ (1999) Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br J Pharmacol 128:13–20
Robertson DW, Bloomquist W, Wong DT, Cohen ML (1992) mCPP but not TFMPP is an antagonist at cardiac 5HT3 receptors. Life Sci 50:599–605
Schlag BD, Lou Z, Fennell M, Dunlop J (2004) Ligand dependency of 5-hydroxytryptamine 2C receptor internalization. J Pharmacol Exp Ther 310:865–870
Schoeffter P, Hoyer D (1989) Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist? Naunyn Schmiedebergs Arch Pharmacol 339:675–683
Sterious SN, Walker EA (2003) Potency differences for d-Phe-Cys-Tyr-d-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid mu-agonists in an antinociception assay. J Pharmacol Exp Ther 304:301–309
Takemori AE (1974) Determination of pharmacological constants: use of narcotic antagonists to characterize analgesic receptors. In: Braude M, Harris LS, May E, Smith JP, Villarreal J (eds) Narcotic antagonists. Raven, New York, pp 335–344
Tallarida RJ, Raffa RB (1992) Receptor regulation, competitive antagonism and pA2. Life Sci 51:PL61–PL65
Vickers SP, Easton N, Malcolm CS, Allen NH, Porter RH, Bickerdike MJ, Kennett GA (2001) Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists. Pharmacol Biochem Behav 69:643–652
Walker EA, Kohut SJ, Hass RW, Brown EK Jr, Prabandham A, Lefever T (2005) Selective and nonselective serotonin antagonists block the aversive stimulus properties of MK212 and m-chlorophenylpiperazine (mCPP) in mice. Neuropharmacology 49:1210–1219
Wenger GR (1980) Cumulative dose–response curves in behavioral pharmacology. Pharmacol Biochem Behav 13:647–651
Wolff MC, Leander JD (2000) A comparison of the behavioural effects of 5-HT2A and 5-HT2C receptor agonists in the pigeon. Behav Pharmacol 11:355–364
Acknowledgment
The authors wish to thank Richard W. Hass, Amy Falcone, and Amy Schneider for their technical assistance. All experiments reported in this manuscript comply with the current laws and research regulations of the State of Pennsylvania and the USA.
Author information
Authors and Affiliations
Corresponding author
Additional information
This research was supported by the National Institute on Drug Abuse Grant DA14673.
Rights and permissions
About this article
Cite this article
Walker, E.A., Brown, E.K. & Sterious, S.N. In vivo Schild regression analyses using nonselective 5-HT2C receptor antagonists in a rat operant behavioral assay. Psychopharmacology 193, 187–197 (2007). https://doi.org/10.1007/s00213-007-0769-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-007-0769-0